Zydus Lifesciences (BOM:532321) 5-Year EBITDA Growth Rate : 12.10% (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences 5-Year EBITDA Growth Rate?

Zydus Lifesciences's EBITDA per Share for the three months ended in Sep. 2024 was ₹15.21.

During the past 12 months, Zydus Lifesciences's average EBITDA Per Share Growth Rate was 49.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 20.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 12.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zydus Lifesciences was 29.90% per year. The lowest was -8.10% per year. And the median was 14.50% per year.

Competitive Comparison of Zydus Lifesciences's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zydus Lifesciences's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's 5-Year EBITDA Growth Rate falls into.

Zydus Lifesciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Zydus Lifesciences (BOM:532321) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Zydus Lifesciences 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.

Zydus Lifesciences Headlines

No Headlines